Table 4.
The age, sex, and geographical distribution of participants and the target population, as well as available national registry data at the close of study recruitment.
| Registered participants | Target population | |
|---|---|---|
| n | 80,759 | 148,704 |
| % females | 54% | 51% |
| median agea | 59 | 57 |
| Age rangea | 40–104 | 40–107 |
| Participation rate | ||
| All | 54% | – |
| Males | 51% | – |
| Females | 58% | – |
| Age group (male/female)a | ||
| 40–49 (%) | 21.2%/23.7% | 27.4%/26.0% |
| 50–59 (%) | 27.7%/29.9% | 29.4%/28.7% |
| 60–69 (%) | 28.4%/26.1% | 23.4%/22.4% |
| 70–79 (%) | 16.6%/14.4% | 12.9%/13.3% |
| 80–89 (%) | 5.7%/5.3% | 6.0%/7.8% |
| >90 (%) | 0.4%/0.5% | 0.9%/1.8% |
| Place of residence | ||
| Reykjavik Capital Area | 58.7% | 62.9% |
| Other urban centersb | 17.5% | 15.6% |
| Rural | 23.3% | 21.1% |
| Missing | 0.6% | 0.4% |
| Known MGUSc | 246 (0.3%) | – |
| Previous LPd | 548 (0.7%) | – |
| Data from registriese | ||
| n hospital admissions | 190,382 | – |
| n primary care visits | 8,187,805 | – |
| n cancers diagnoses | 10,328 | – |
| n prescriptions | 15,839,376 | – |
aAge at the time of study initiation on September 9th, 2016.
bUrban centers with >5000 inhabitants outside the Capital area.
cAs registered before study enrollment in the Icelandic Cancer Registry since 1955, Icelandic Central Laboratory Database since 1999. and a registry of MGUS cases at Icelandic Private Clinics.
dAs recorded before study enrollment in the Icelandic Cancer Registry since 1955.
eAs recorded in national registries at the close of study enrollment on February 20th, 2018.